Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: Indazole and benzimidazolone derivatives

Journal of Medicinal Chemistry

Volumn 41, Issue 11, 1998, Pages 1943-1955

  Schaus, John M ^a   Thompson, Dennis C ^a   Bloomquist, William E ^a   Susemichel, Alice D ^a   Calligaro, David O ^a   Cohen, Marlene L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHYLETHYL) N [2 [4 [(TRICYCLO[3.3.1.1]DEC 1 YLCARBONYL)AMINO] 1 PIPERIDINYL]ETHYL] 1H INDAZOLE 3 CARBOXAMIDE; N [2 [4 (1 ADAMANTANECARBOXAMIDO) 1 PIPERIDINYL]ETHYL] 1 ISOPROPYL 1H INDAZOLE 3 CARBOXAMIDE; SEROTONIN 4 ANTAGONIST; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROGEN BOND; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ANALYSIS;

ADAMANTANE; ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AORTA; BRAIN; DRUG EVALUATION, PRECLINICAL; ESOPHAGUS; GUINEA PIGS; ILEUM; INDAZOLES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032554869     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970857f     Document Type: Article

References (41)

1. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46 (2), 157.
2. 4 receptors: physiology, pharmacology and therapeutic potential. Exp. Opin. Invest. Drugs 1996, 5 (4), 373.
3. 4 receptors: physiology, pharmacology and therapeutic potential. Exp. Opin. Invest. Drugs 1996, 5 (4), 373.
4. 4 receptors: physiology, pharmacology and therapeutic potential. Exp. Opin. Invest. Drugs 1996, 5 (4), 373.
5. Dumuis, A.; Bouhelal, R.; Sebben, M.; Cory, R.; Bockaert, J. A. nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol. 1988, 34, 880.
6. (a) Gerald, C.; Adham, N.; Kao, H.-T.; Olsen, M. A.; Laz, T. M.; Schechter, L. E.; Bard, J. A.; Vaysse, P. J. J.; Hartig, P. R.; Branchek, T. A.; Weinshank, R. L. The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J. 1995, 14, 2806.
7. (b) Ullmer, C.; Schmuck, K.; Kalkman, H. O.; Lubbert, H. Expression of Serotonin receptor mRNAs in blood vessels. FEBS Lett. 1995, 370, 215.
8. 4 receptor subtype inhibits potassium current in colliculi neurons via activation of a cyclic AMP-dependent protein kinase. Br. J. Pharmacol. 1992, 105, 973.
9. 4 Receptor Antagonist: Comparison to Cisapride and RS23597-190. J. Pharmacol. Exp. Ther. 1996, 277, 97.
10. 4) receptors. Br. J. Parmacol. 1993, 108, 376.
11. 4 Receptors in Rat but not Guinea Pig, Rabbit or Dog Esophageal Smooth Muscle. Gen. Pharmacol. 1994, 25 (6), 1143.
12. Gale, J. D.; Grossman, C. J.; Whitehead, J. W. F.; Oxford, A. W.; Bunce, K. T.; Humphrey, P. P. A. GR 113, 808: a novel selective antagonist with high affinity at the 5-HT4 receptor. Br. J. Pharmacol. 1994, 111, 332.
13. 4 receptor antagonist, on guinea pig distal colon. Br. J. Pharmacol. 1994, 112, 789.
14. 4 Receptor Antagonist RS-23597 are High Affinity Partial Agonists. Bioorg. Med. Chem. Lett. 1994, 20, 2477.
15. 4 receptor antagonism by SB 207266. Br. J. Pharmacol. 1996, 118, 665.
16. 4 receptor antagonist. BioOrg. Med. Chem. Lett. 1995, 5, 2119.
17. McGill, J.; LaBell, E.; Williams, M. Hydride Reagents for Stereoselective Reductive Amination. An Improved Preparation of 3-endo-Tropanamine. Tetrahedron Lett. 1996, 37, 3977.
18. Ainsworth, C. Indazole Analogue of Tryptamine: A New Synthesis of Indazoles. J. Am. Chem. Soc. 1957, 79, 5242.
19. While the alkylation of indazole-3-carboxylic esters and of indazole itself is known to give regiochemical mixtures of N-1 and N-2 alkylated products, the alkylation of amide 12a predominantly gave the N-l alkylated product. It is believed that internal hydrogen bonding between the amide N-H and N-2 (i) deactivates N-2 to alkylation and directs alkylation to N-1.
20. 3 Receptor Antagonists. J. Med. Chem. 1990, 33, 2101.
21. 3 Receptor Antagonists. J. Med. Chem. 1990, 33, 2942.
22. 3 receptor antagonist: synthesis and structure-activity relationships. J. Med. Chem. 1992, 35, 310.
23. (a) Reeves, J. J.; Bunce, K. T.; Humphrey, P. P. A. Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus. Br. J. Pharmacol. 1991, 103, 1067.
24. 4 receptors mediated relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn-Schmiedeberg's Arch. Pharmacol. 1991, 343, 439.
25. See ref 11 for another example in which amides possessed higher efficacy (i.e., greater agonist activity) than the corresponding esters.
26. 4 receptors and potential therapeutic implications. Drugs Future 1991, 16, 1011.
27. 2 receptor affinity. J. Med. Chem. 1987, 30, 1823.
28. 2 and rat stomach fundal serotonin receptors. J. Med. Chem. 1986, 29, 2415.
29. de Paulis, T. Substituted Benzamides. The development of selective dopamine antagonists. In VIIth International Symposium on Medicinal Chemistry, Proceedings, Vol. 1; Dahlbom, R., Nilsson, J. L. G., Eds.: Swedish Pharmaceutical Press: Stockholm, 1985; p 405.
30. b = 8.40) (Cohen, M. L.; Robertson, D. W.; Susemichel, A. D.; Krushinski, J. K. Unpublished results).
31. Richardson, B. P.; Engel, G.; Donatsch, P.; Stadler, P. A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985, 316, 126.
32. 3 Receptor antagonist Properties of ICS 205-930, GR38032F and Zacopride. J. Pharmacol. Exp. Ther. 1989, 248, 197.
33. 3 receptor antagonist without gastroprokinetic activity. J. Pharmacol. Exp. Ther. 1990, 254, 350.
34. 3 Receptors; Hamon, M.; Ed.; Academic Press: London, 1995; Chapter 4, p 59.
35. 3H]-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 1979, 55, 323.
36. 2 receptors mediating contraction in vascular smooth muscle. J. Pharmacol. Exp. Ther. 1981, 218, 421.
37. 4 receptor function. J. Pharm. Pharmacol. 1995, 47, 219.
38. 4) receptors. Br. J. Pharmacol. 1993, 108, 376.
39. 4 receptor antagonist. Br. J. Pharmacol. 1993, 110, 119.
40. 4 receptor antagonist activity in vitro, yet no ex vivo inhibition of esophageal relaxation to serotonin occurred at a dose (1.0 mg/kg) 10-fold higher than the inhibitory dose of 8. This finding is consistent with the conclusion that the activity of compounds in this ex vivo assay following oral administration is due to systemic absorption rather than through localized effects.
41. See ref 6 for a detailed report on the pharmacology of 8.